"On Thursday, President Donald Trump announced that two blockbuster weight-loss drugs Wegovy and Zepbound (which are also available for Diabetes treatment under the brand names Ozempic and Mounjaro, respectively) would become dramatically more affordable thanks to new federal subsidies. An executive for Eli Lily fainted minutes later, and cable news did what cable news does and had a field day with Trump's bizarre reaction captured by a pool photographer."
"Americans carry a heavy burden literally. Roughly 42% of U.S. adults now live with obesity, nearly double the rate from 30 years ago. That shift costs us an estimated $170 billion a year in medical spending, and the bill is climbing. These drugs, which can cut body weight by 1520%, are not cosmetic; they're the rare intervention that could meaningfully change life expectancy at a massive scale."
"Imagine a country with fewer amputations, fewer heart attacks, fewer CPAP machines humming through the night. Even a 10% reduction in obesity prevalence would save tens of billions and give millions more people back their knees, their breath, their literal second chance. I know because I lived it. Over the past year or so, I've lost more than 70 pounds on Zepbound. No, I didn't get my shapely form back"
Federal action will make Wegovy and Zepbound (also available as Ozempic and Mounjaro for diabetes) far more affordable through new subsidies. The announcement coincided with an Eli Lilly executive fainting and intense media focus on that incident rather than the policy. About 42% of U.S. adults have obesity, nearly double the rate from 30 years ago, costing roughly $170 billion annually in medical spending. These drugs can reduce body weight by 15–20% and have potential to lower amputations, heart attacks, and sleep apnea, raise life expectancy, and save tens of billions even with modest prevalence reductions. Personal reports show substantial weight loss on Zepbound.
Read at www.mediaite.com
Unable to calculate read time
Collection
[
|
...
]